Skip to search formSkip to main contentSkip to account menu

FG 3019

Known as: Anti-Connective Tissue Growth Factor Monoclonal Antibody FG-3019, FG-3019, Anti-CTGF Monoclonal Antibody FG-3019 
A human monoclonal antibody targeting connective tissue growth factor (CTGF) with potential anti-fibrotic and antineoplastic activities. FG-3019… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Monoclonal Antibodies
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model
Malignant mesothelioma is an aggressive neoplasm with no particularly effective treatments. We previously reported that… 
2017
2017
Late Breaking Abstract - Responder phenotyping using functional respiratory imaging (FRI) in IPF patients treated with anti-CGTG monoclonal antibody FG3019
Aims and objectives To identify baseline FRI parameters that predict changes in FVC and fibrosis after 48w of treatment with… 
2016
2016
FG-3019, A Human Monoclonal Antibody to Connective Tissue Growth Factor, Combined with Chemotherapy in Patients with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Purpose: Connective tissue growth factor (CTGF) is overexpressed in pancreatic ductal adenocarcinoma (PDAC) and facilitates local… 
2015
2015
A randomized, open-label, phase I/II trial of gemcitabine plus nab-paclitaxel with or without FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer.
TPS500 Background: Only 15% of patients with pancreatic ductal adenocarcinoma (PDAC) are eligible for resection. Patients with… 
2014
2014
Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth
Connective tissue growth factor (CTGF/CCN2) is involved in extracellular matrix production, tumor cell proliferation, adhesion… 
2014
2014
FG-3019, a human monoclonal antibody to connective tissue growth factor (CTGF), with gemcitabine/erlotinib (G/E) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC…
4138 Background: CTGF is overexpressed in PDAC and facilitates local desmoplasia, tumor survival and metastasis. FG-3019 is a… 
2013
2013
FG-3019, a human monoclonal antibody to CTGF, with gemcitabine/erlotinib in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
213 Background: Connective tissue growth factor (CTGF) is overexpressed in PDAC and facilitates local desmoplasia, tumor survival… 
2012
2012
Phase 2 trial of FG-3019, anti-CTGF monoclonal antibody, in idiopathic pulmonary fibrosis (IPF): Preliminary safety and efficacy results
Introduction: Connective tissue growth factor (CTGF) is implicated in the pathogenesis of IPF and is a potential novel… 
2011
2011
A phase I trial of the monoclonal antibody FG-3019 to connective tissue growth factor (CTGF) in locally advanced or metastatic pancreatic cancer.
269 Background: CTGF is highly expressed in pancreatic tumors and is thought to mediate local desmoplasia. FG-3019 is a fully… 
2011
2011
Rapid reversal of radiation-induced murine pneumonitis by treatment with the anti-CTGF monoclonal antibody FG-3019
Rationale: Connective tissue growth factor (CTGF) is a matricellular protein that is a central mediator of tissue remodeling… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)